The role of interleukin-6 signaling in nervous tissue.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and preclinical literature without primary data.
PubMed 27016501 · doi:10.1016/j.bbamcr.2016.03.018
What was done
This narrative review summarizes the physiological and pathological roles of interleukin-6 (IL-6) signaling in neural tissue. The authors describe the dichotomy between classical signaling via membrane-bound IL-6 receptor (IL-6R) and pro-inflammatory trans-signaling via soluble IL-6R, as well as preclinical evidence on the selective inhibitor sgp130Fc in neurological contexts.
What was found
The abstract reports no quantitative values or statistical comparisons. It summarizes qualitative observations: elevated IL-6 is associated with multiple sclerosis, Parkinson's disease, Alzheimer's disease, and impaired nocturnal sleep; IL-6 knockout mice exhibit increased rapid eye movement sleep; classical signaling facilitates oligodendrocyte differentiation and nerve regeneration; and recombinant soluble gp130 (sgp130Fc) selectively blocks pro-inflammatory trans-signaling in mice while preserving classical signaling.
Why it matters
Distinguishing IL-6 classical signaling from trans-signaling resolves how the cytokine can be simultaneously neuroprotective and neurodestructive, establishing a theoretical basis for targeting trans-signaling therapeutically without compromising host defense.
Limits
The abstract describes a non-systematic narrative review with no defined search criteria, study selection methods, or statistical pooling. Much of the mechanistic and therapeutic evidence relies on murine models, and human clinical relevance remains unquantified.
Cited by
- supports The brain expresses receptors for IL-6.